Compositions Comprising Flumazenil and Naltrexone and Methods of Use Thereof

JP2024501919A5Active Publication Date: 2024-11-12TREXAPHARM PTY LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023532700
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-11-27
Filing Date
2021-11-26
Publication Date
2024-11-12
Estimated Expiration
2041-11-26

AI Technical Summary

Technical Problem

Current treatments for depression, anxiety, and PTSD face limitations such as social stigma, limited treatment options, unaffordability, adverse side effects, and patient non-compliance, with some patients being unresponsive to existing therapies.

Method used

A combination of low-dose flumazenil and low-dose naltrexone, administered in specific weight ratios, is used to treat depression, anxiety, and PTSD, with formulations suitable for various routes of administration including oral, transmucosal, transdermal, and parenteral methods.

Benefits of technology

The combination of flumazenil and naltrexone effectively improves symptoms of depression, anxiety, and PTSD, allowing patients to perform daily tasks and enhances mood and concentration, even in treatment-resistant cases, with potential for sustained or immediate release formulations.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present invention relates to a pharmaceutical composition comprising flumazenil and naltrexone, in particular a composition comprising low dose flumazenil and low dose naltrexone. The present invention also relates to a method of using the combination of flumazenil and naltrexone in the treatment of depression and / or anxiety and / or post-traumatic stress disorder (PTSD).
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a pharmaceutical composition comprising flumazenil and naltrexone, in particular a composition comprising low dose flumazenil and low dose naltrexone.The present invention also relates to a method of using a combination of flumazenil and naltrexone in the treatment of depression and / or anxiety and / or post-traumatic stress disorder (PTSD).The present invention further relates to a kit comprising one or more pharmaceutical compositions. [Background technology]

[0002] Flumazenil and naltrexone are over-the-counter medications. Flumazenil is a GABA antagonist used commercially to reverse the effects of benzodiazepine sedation, usually administered intravenously. Naltrexone is an opioid receptor antagonist used commercially in high doses for the management of opioid or alcohol addiction. When used in high doses, it is usually administered orally, by intramuscular injection or subcutaneous implant. Naltrexone is used "off-label" in lower doses for conditions unrelated to addiction.

[0003] Depression is a condition that affects physical and mental health and is a leading cause of death and disability worldwide, with post-traumatic stress disorder (PTSD) being a comorbidity with depression. Anxiety disorders are also common mental illnesses worldwide. Currently, there are treatments available for depression, PTSD, and anxiety disorders, including behavioral and pharmacological therapy. However, there are limitations that impede treatment acceptance, such as lack of education, social stigma, limited treatment options, and unaffordable prices, leading to an unmet need for treatment. With regard to current pharmacotherapies, factors such as adverse side effects, contraindications, intolerance, need for multiple medications, and inconvenience of taking or administering medications may also lead to poor patient compliance. In addition, some patients have been found to be unresponsive to current pharmacotherapies. Summary of the Invention [Problem to be solved by the invention]

[0004] Thus, there is a need for alternative therapies that can be used to treat depression, anxiety, and post-traumatic stress disorder that can address one or more of the limitations associated with current treatments. [Means for solving the problem]

[0005] overview The present invention is based, at least in part, on the discovery that a combination of microdosed flumazenil and microdosed naltrexone may be useful in the treatment of conditions such as depression, anxiety and PTSD. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0006] In one embodiment of the present invention, there is provided a pharmaceutical composition comprising flumazenil and naltrexone, or a pharma- ceutically acceptable salt thereof, wherein the flumazenil and naltrexone are present in a weight ratio of about 300:1 to about 2:1.

[0007] In another aspect of the present invention, there is provided a method for treating depression comprising administering to a patient in need thereof a combination of flumazenil and naltrexone, or pharma- ceutically acceptable salts thereof, wherein the flumazenil and naltrexone are administered in a weight ratio of about 300:1 to about 2:1.

[0008] In a further aspect of the present invention, there is provided a method for treating anxiety comprising administering to a patient in need thereof a combination of flumazenil and naltrexone, or pharma- ceutically acceptable salts thereof, wherein the flumazenil and naltrexone are administered in a weight ratio of about 300:1 to about 2:1.

[0009] In a further aspect of the present invention, there is provided a method for treating post-traumatic stress disorder comprising administering to a patient in need thereof a combination of flumazenil and naltrexone, or pharma- ceutically acceptable salts thereof, wherein the flumazenil and naltrexone are administered in a weight ratio of about 300:1 to about 2:1.

[0010] In yet another aspect of the present invention, there are provided kits comprising one or more pharmaceutical compositions described herein and, optionally, a delivery device.

[0011] Detailed Description 1.Definition Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are described. For the purposes of the present invention, the following terms are defined below.

[0012] The articles "a" and "an" are used herein to refer to one or to more than one (i.e., to at least one) of the grammatical object of the article. By way of example, "an element" means one element or more than one element.

[0013] As used herein, the term "about" indicates an amount, value, dimension, size, or amount that varies to the same extent as 30%, 25%, 20%, 15%, or 10% from a reference amount, value, dimension, size, or amount.

[0014] As used herein, unless the context otherwise requires, the word "comprise", and variations such as "comprises" and "comprising", are understood to imply the inclusion of a stated integer or step, or group of integers or steps, but not the exclusion of other integers or steps, or groups of integers or steps.

[0015] 2. Pharmaceutical Compositions The present invention provides a pharmaceutical composition comprising flumazenil and naltrexone or a pharma- ceutically acceptable salt thereof.

[0016] The composition contains a specific weight amount of flumazenil relative to naltrexone. The inventors arrived at the specific ratio and amount of flumazenil and naltrexone based on observations made in many previous studies and taking into account the relative bioavailability of flumazenil and naltrexone by different routes of administration.

[0017] In some embodiments, the flumazenil and naltrexone are present in the composition in a weight ratio of flumazenil to naltrexone of about 300:1 to about 2:1. In some embodiments, the flumazenil and naltrexone are present in the composition in a weight ratio of flumazenil to naltrexone of about It exists at 300:1, 280:1, 260:1, 250:1, 240:1, 220:1, 200:1, 180:1, 160:1, 150:1, 140:1, 120:1, 100:1, 90:1, 80:1, 70:1, 60:1, 50:1, 45:1, 40:1, 35:1, 30:1, 28:1, 26:1, 25:1, 24:1, 22:1, 20:1, 19:1, 18:1, 17:1, 16:1, 15:1, 14:1, 13:1, 25:2, 12:1, 11:1, 10:1, 9:1, 8:1, 7:1, 6:1, 5:1, 4:1, 3:1, or 2:1. Any ratio of flumazenil and naltrexone can be combined to form a range, provided the range is within the range of 300:1 to 2:1, for example, from about 30:1 to about 4:1, or from about 25:1 to about 10:1.

[0018] In some embodiments, the composition is in the form of a single dosage unit that can be administered to a patient during treatment. The amount of flumazenil and naltrexone contained in the composition or single dosage unit can be appropriately selected depending on the treatment plan. In some embodiments, the single dosage unit is formulated for administration over a range of about 1 day to about 10 days. In some embodiments, the single dosage unit is formulated for administration over about 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, or 10 days, particularly about 4 days.

[0019] In some embodiments, a single dosage unit (or composition) contains flumazenil in an amount to provide a daily dose in the range of about 250 to about 7,500 micrograms. In some embodiments, a single dosage unit contains flumazenil in an amount to provide a daily dose of about 250; 500; 750; 1,000; 1,250; 1,500; 1,750; 2,000; 2,250; 2,500; 2,750; 3,000; 3,250; 3,500; 3,750; 4,000; 4,250; 4,500; 4,750; 5,000; 5,250; 5,500; 5,750; 6,000; 6,250; 6,500; 6,750; 7,000; 7,250; or 7,500 micrograms. Any minimum and maximum values ​​can be combined to form a range, so long as the range is within 250 to 7,500 micrograms, such as a range of about 2,000 to about 5,000 micrograms, or about 2,500 to about 4,500 micrograms.

[0020] In some embodiments, a single dosage unit (or composition) contains naltrexone in an amount that provides a daily dose in the range of about 25 to about 1,000 micrograms. In some embodiments, a single dosage unit contains naltrexone in an amount that provides a daily dose of about 25; 50; 75; 100; 125; 150; 175; 200; 225; 250; 275; 300; 325; 350; 375; 400; 425; 450; 475; 500; 550; 600; 650; 700; 750; 800; 850; 900; 950; or 1,000 micrograms. Any minimum and maximum values ​​can be combined to form a range within 25 to 1,000 micrograms, such as a range of about 100 to about 600 micrograms, or about 200 to about 400 micrograms.

[0021] In some embodiments, flumazenil is present in a single dosage unit (or composition) in an amount ranging from about 1,000 to about 30,000 micrograms. In some embodiments, flumazenil is present in an amount of about 1,000; 2,000; 3,000; 4,000; 5,000; 6,000; 7,000; 8,000; 9,000; 10,000; 11,000; 12,000; 13,000; 14,000; 15,000; 16,000; 17,000; 18,000; 19,000; 20,000; 21,000; 22,000; 23,000; 24,000; 25,000; 26,000; 27,000; 28,000; 29,000; or 30,000 micrograms. Any minimum and maximum values ​​can be combined to form a range, so long as the range is within 1,000 to 30,000 micrograms, such as a range of about 8,000 to about 20,000 micrograms, or about 10,000 to about 18,000 micrograms.

[0022] In some embodiments, naltrexone is present in a single dosage unit (or composition) in an amount ranging from about 100 to about 4,000 micrograms. In some embodiments, naltrexone is present in an amount of about 100; 200; 300; 400; 500; 600; 700; 800; 900; 1000; 1,100; 1,200; 1,300; 1,400; 1,500; 1,600; 1,700; 1,800; 1,900; 2,000; 2,200; 2,400; 2,600; 2,800; 3,000; 3,200; 3,400; 3,600; 3,800; or 4,000 micrograms. Any minimum and maximum values ​​can be combined to form a range, provided the range is within 100 to 4,000 micrograms, such as a range of about 400 to about 2,400 micrograms, or about 800 to about 1,600 micrograms.

[0023] The pharmaceutical composition may be appropriately formulated for administration by a particular route. Suitable administration routes include oral, mucosal, transdermal, and parenteral administration. In some embodiments, the composition is formulated for oral administration, topical administration such as buccal or sublingual administration, nasal administration, transdermal administration, or parenteral administration such as subcutaneous or intramuscular administration. In certain embodiments, the composition is formulated for parenteral administration, particularly subcutaneous administration. In other particular embodiments, the composition is formulated for nasal administration. The ratio and amount of flumazenil and naltrexone in the composition may be appropriately selected based on the relative bioavailability of each compound for a particular administration route.

[0024] In some embodiments, the pharmaceutical composition comprises a pharma- ceutically acceptable carrier or excipient. The excipient must be "acceptable" in the sense of being compatible with the other ingredients of the composition and not deleterious to the recipient thereof. Suitable excipients include edetate disodium and sodium chloride.

[0025] Pharmaceutical preparations include those suitable for oral, topical (including buccal and sublingual), nasal or parenteral (including subcutaneous, intramuscular and intravenous) administration, or in a form suitable for administration by inhalation or insufflation. Thus, the combinations of the present invention, together with conventional adjuvants, carriers, excipients, or diluents, can be placed into the form of pharmaceutical compositions and unit doses thereof, and in such form can be employed as solids, such as tablets or filled capsules, all for oral use, or liquids, such as solutions, suspensions, emulsions, elixirs, or capsules filled therewith, aqueous suspensions for use in nasal spray formulations, or sterile injectable solutions for parenteral (including subcutaneous) use. Such compositions and unit dose forms thereof can contain conventional ingredients in conventional proportions, with or without additional active compounds or principles, and such unit dose forms can contain any suitable combination of effective amounts according to the intended daily dose range used as described herein. The compounds of the present invention can be administered in a wide variety of oral and parenteral dosage forms. It will be understood by those skilled in the art that the following dosage forms may contain flumazenil and naltrexone, or pharma- ceutically acceptable salts thereof.

[0026] For preparing the pharmaceutical composition of the present invention, pharmaceutically acceptable carrier can be either solid or liquid.Solid preparations include powder, tablet, pill, capsule, cachet, suppository and dispersible granule.Solid carrier can be one or more substances that also function as diluent, flavoring agent, solubilizer, lubricant, suspending agent, binder, preservative, tablet disintegrating agent or encapsulating material.

[0027] In powders, the carrier is a finely divided solid, which is in a mixture with the finely divided active ingredient.

[0028] In tablets, the active ingredient is mixed with a carrier having the necessary binding capacity in suitable proportions and compressed into the desired shape and size.

[0029] The powders and tablets preferably contain from 5 or 10 to about 70 percent of the active compound. Suitable carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, low melting wax, cocoa butter, and the like. The term "composition" is intended to include formulations of flumazenil and naltrexone with or without a carrier, with an encapsulating material as a carrier, providing a capsule in which flumazenil and naltrexone are surrounded by the carrier, thus binding the flumazenil and naltrexone. Similarly, cachets and lozenges are also included. Tablets, powders, capsules, cachets, lozenges, and the like can be used as solid preparations suitable for oral administration.

[0030] Liquid form formulations include solutions, suspensions, and emulsions, such as water or water-propylene glycol solutions. For example, parenteral injection liquid formulations can be formulated as solutions in aqueous polyethylene glycol solutions. In another example, nasal sprays can be formulated as aqueous solutions or suspensions in water. In embodiments where the formulation is a liquid, the liquid preferably has a pH of about 4.6 or higher, particularly a pH of about 4.6 to 4.8, and more particularly a pH of about 4.7.

[0031] Thus, flumazenil and naltrexone may be formulated for parenteral administration (e.g., by injection, such as bolus injection or continuous infusion) and provided in unit dose form in ampoules, prefilled syringes, small injections, or multi-dose containers with added preservatives. The compositions may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles and may contain formulating agents such as suspending, stabilizing, and / or dispersing agents. Alternatively, flumazenil and naltrexone may be in powder form, obtained by aseptic isolation of sterile solids or lyophilization from solution, for constitution with a suitable vehicle, such as sterile pyrogen-free water, before use.

[0032] Aqueous solutions suitable for oral use can be prepared by dissolving flumazenil and naltrexone in water and adding suitable colorants, flavors, stabilizing and thickening agents as desired.

[0033] Aqueous suspensions suitable for oral use can be prepared by dispersing finely divided flumazenil and naltrexone in water with a viscous substance such as a natural or synthetic gum, resin, methylcellulose, sodium carboxymethylcellulose or its salts, or other well-known suspending agent.

[0034] Also included are solid preparations that are intended to be converted immediately before use into liquid preparations for oral administration. Such liquid forms include solutions, suspensions, and emulsions. These preparations may contain, in addition to the active ingredient, colorants, flavors, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizers, etc.

[0035] The solution or suspension is applied directly to the nasal cavity by conventional means such as a dropper, pipette or spray. The formulation is provided in single or multi-dose form. In the latter case of a dropper or pipette, this is achieved by the patient administering an appropriate, predetermined amount of the solution or suspension. In the case of a spray, this can be achieved, for example, by a metered-dose spray pump. To improve nasal delivery and retention, flumazenil and naltrexone can be encapsulated with cyclodextrin or formulated with agents expected to enhance delivery and retention at the nasal mucosa. Nasal formulations can also include preservatives such as benzalkonium chloride.

[0036] Administration to the respiratory tract may also be achieved by aerosol formulation in which flumazenil and naltrexone are provided in a pressurized pack with a suitable propellant, such as a hydrofluoroalkane (HFA) or chlorofluorocarbon (CFC), e.g., dichlorodifluoromethane, trichlorofluoromethane, or dichlorotetrafluoroethane, carbon dioxide, or other suitable gas. The aerosol may conveniently also contain a surfactant, such as lecithin. The dosage of the drug may be controlled by providing a metered valve.

[0037] Alternatively, flumazenil and naltrexone may be provided in the form of a dry powder, for example a powder mix of the compounds in a suitable powder base such as lactose, starch, hydroxypropylmethylcellulose and starch derivatives such as polyvinylpyrrolidone (PVP).

[0038] Conveniently, the powder carrier will form a gel in the nasal cavity.The powder composition may be presented in unit dose form, for example, in capsules or cartridges of gelatin, or blister packs from which the powder may be administered by means of an inhaler.

[0039] In formulations intended for administration to the respiratory tract, including intranasal formulations, the compound will generally have a small particle size, for example of the order of 1 to 50 microns or less, Such a particle size may be obtained by means known in the art, for example by micronization.

[0040] If necessary, preparations adapted to sustained release of the active ingredient can be used.

[0041] In embodiments where the pharmaceutical composition is in a single dosage unit form, the unit dosage form can be a packaged composition, i.e., a package containing discrete quantities of composition, such as tablets, capsules, and powders in vials or ampoules.Also, the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.

[0042] In some embodiments, the pharmaceutical composition (or single dose unit) is contained in a delivery device. Delivery devices suitable for nasal administration include nasal sprays. Delivery devices suitable for transdermal administration include transdermal patches and implants. Delivery devices suitable for parenteral administration, such as subcutaneous administration, include infusion pumps, such as portable infusion pumps.

[0043] The pharmaceutical compositions may be suitably formulated to allow for immediate, delayed, or sustained release of flumazenil and naltrexone.

[0044] The pharmaceutical composition described herein may be included in a pharmaceutical product or kit.The kit may include one or more pharmaceutical compositions of the present invention, and each composition may be in the form of a single dosage unit as described herein.The single dosage unit may be in any suitable form as described herein. The kit may optionally include a device for delivering the pharmaceutical composition or the single dosage unit.

[0045] Thus, in one aspect of the present invention, a kit is provided that includes one or more pharmaceutical compositions as described herein and optionally a delivery device.The delivery device can be any suitable delivery device as described herein.The delivery device can be suitably adapted to deliver a single dosage unit over a period of time.The delivery device can also be suitably adapted to allow the exchange or replacement of the single dosage unit.

[0046] In certain embodiments, the kit includes one or more parenteral dosage units suitable for subcutaneous delivery over one or more days, e.g., about 2, 3, or 4 days, and a syringe pump suitable for delivering the dosage units over a period of time. In some embodiments, replacement doses may be included in the kit to provide multiple dosage units delivered continuously over, e.g., about 2, 3, 4, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16 days, or any period between these delivery periods.

[0047] 3.How to use The combination of flumazenil and naltrexone may be useful in treating depression. Accordingly, the present invention provides a method of treating depression, comprising administering to a patient in need thereof a combination of flumazenil and naltrexone, or pharma- ceutically acceptable salts thereof, wherein the flumazenil and naltrexone are administered in a weight ratio of about 300:1 to about 2:1.

[0048] The phrase "treat depression" in this context refers to the improvement of symptoms related to depression, and the improvement can be characterized qualitatively or quantitatively by evaluations known in the art. The depression can be treatment-resistant depression, where the patient has not responded to antidepressants before. Examples of types of depression or major depressive disorder include depression with melancholic features or somatic syndromes, depression with psychotic features, depression with atypical features, depression with catatonic features, depression with anxiety distress, and depression with mixed features. All types of depressive episodes can have a pattern of illness, such as single, recurrent, seasonal, or persistent, and / or can be related to organic causes (such as those caused by medication-induced or behavioral and psychological symptoms of dementia (BPSD)) and neuroendocrine disorders, such as premenstrual dysphoric disorder, perimenopausal, or perinatal (including prenatal and postnatal) depression.

[0049] A combination of flumazenil and naltrexone may also be useful in treating anxiety. Accordingly, the present invention provides a method of treating anxiety comprising administering to a patient in need thereof a combination of flumazenil and naltrexone, or pharma- ceutically acceptable salts thereof, wherein the flumazenil and naltrexone are administered in a weight ratio of about 300:1 to about 2:1.

[0050] The phrase "treat anxiety" in this context refers to the improvement of anxiety symptoms, and the improvement can be characterized qualitatively or quantitatively by evaluations known in the art. Examples of types of anxiety include generalized anxiety disorder, social anxiety disorder, panic disorder, specific phobia, and post-traumatic stress disorder. In the context of the present invention, the combination of flumazenil and naltrexone may be useful for treating anxiety in general, but does not necessarily exclude anxiety associated with craving for smoking, alcohol, or drug use. Thus, in certain embodiments, the anxiety is not associated with craving, such as smoking craving or dependency.

[0051] The combination of flumazenil and naltrexone can be useful in treating PTSD. Accordingly, the present invention provides a method for treating PTSD, comprising administering to a patient in need thereof a combination of flumazenil and naltrexone, or a pharma- ceutically acceptable salt thereof, wherein flumazenil and naltrexone are administered in a weight ratio of about 300:1 to about 2:1.

[0052] The treatment may also reduce symptoms of depression, anxiety, and PTSD. For example, treatment may enable patients to perform everyday tasks such as showering, cleaning, shopping, and planning future events that were not possible before treatment. Treatment may also result in improvements in mood, sex drive, and concentration.

[0053] As used herein, the term "combination" refers to flumazenil and naltrexone administered in a single composition or separately, either simultaneously or sequentially. Flumazenil and naltrexone may be administered at different times and with different frequencies, but when used in combination, they exert a biological effect at the same time or at overlapping times.

[0054] In some embodiments, the combination may be administered to patients who have previously failed to respond to antidepressant or anti-anxiety therapy.

[0055] The patient to be treated may already be undergoing treatment for depression, anxiety, PTSD, or one or more other pre-existing conditions. Thus, the combination of flumazenil and naltrexone may be administered in combination with other therapies. In some embodiments, the patient is currently undergoing treatment for depression or anxiety. In these embodiments, the combination of flumazenil and naltrexone may be added to or substituted for current antidepressant or anti-anxiety therapy and related therapy, such as psychotherapy. It may also be used in combination with or prior to neurostimulation therapy, such as transcranial magnetic stimulation (TMS), electroconvulsive therapy (ECT), transcranial direct current stimulation (tDCS), etc.

[0056] The combination includes therapeutically effective amounts of flumazenil and naltrexone, hi some embodiments, the flumazenil and naltrexone are administered in a weight ratio of about 300:1 to about 2:1 flumazenil to naltrexone. In some embodiments, the flumazenil and naltrexone are administered in a weight ratio of about 300:1, 280:1, 260:1, 250:1, 240:1, 220:1, 200:1, 180:1, 160:1, 150:1, 140:1, 120:1, 100:1, 90:1, 80:1, 70:1, 60:1, 50:1, 45:1, 40:1, 35:1, 30:1, 28:1, 26:1, 25:1, 24:1, 22:1, 20:1, 19:1, 18:1, 17:1, 16:1, 15:1, 14:1 , 13:1, 25:2, 12:1, 11:1, 10:1, 9:1, 8:1, 7:1, 6:1, 5:1, 4:1, 3:1, or 2:1. Any ratio of flumazenil and naltrexone can be combined to form a range within the range of 300:1 to 2:1, such as a range of about 30:1 to about 4:1, or about 25:1 to about 10:1.

[0057] In some embodiments, flumazenil is administered to provide a daily dose ranging from about 250 to about 7,500 micrograms. In some embodiments, flumazenil is administered in an amount to provide a daily dose of about 250; 500; 750; 1,000; 1,250; 1,500; 1,750; 2,000; 2,250; 2,500; 2,750; 3,000; 3,250; 3,500; 3,750; 4,000; 4,250; 4,500; 4,750; 5,000; 5,250; 5,500; 5,750; 6,000; 6,250; 6,500; 6,750; 7,000; 7,250; or 7,500 micrograms. Any minimum and maximum values ​​can be combined to form a range, so long as the range is within 250 to 7,500 micrograms, such as a range of about 2,000 to about 5,000 micrograms, or about 2,500 to about 4,500 micrograms.

[0058] In some embodiments, naltrexone is administered to provide a daily dose in the range of about 25 to about 1,000 micrograms. In some embodiments, naltrexone is administered in an amount to provide a daily dose of about 25; 50; 75; 100; 125; 150; 175; 200; 225; 250; 275; 300; 325; 350; 375; 400; 425; 450; 475; 500; 550; 600; 650; 700; 750; 800; 850; 900; 950; or 1,000 micrograms. Any minimum and maximum values ​​can be combined to form a range within 25 to 1,000 micrograms, such as a range of about 100 to about 600 micrograms, or about 200 to about 400 micrograms.

[0059] In some embodiments, flumazenil is administered to provide a total dose in the range of about 4,000 to about 120,000 micrograms over the course of treatment. In some embodiments, flumazenil is administered to provide a total dose of about 4,000; 8,000; 12,000; 16,000; 20,000; 24,000; 28,000; 32,000; 36,000; 40,000; 44,000; 48,000; 52,000; 56,000; 60,000; 64,000; 68,000; 72,000; 76,000; 80,000; 84,000; 88,000; 92,000; 96,000; 100,000; 104,000; 108,000; 112,000; 116,000 or 120,000. Any minimum and maximum values ​​can be combined to form a range, so long as the range is within 4,000 to 120,000 micrograms, such as a range of about 32,000 to about 80,000 micrograms, or about 40,000 to about 72,000 micrograms.

[0060] In some embodiments, naltrexone is administered to provide a total dose in the range of about 400 to about 16,000 micrograms over the course of treatment. In some embodiments, naltrexone is administered to provide a total dose of about 400; 800; 1,200; 1,600; 2,000; 2,400; 2,800; 3,200; 3,600; 4,000; 4,400; 4,800; 5,200; 5,600; 6,000; 6,400; 6,800; 7,200; 7,600; 8,000; 8,800; 9,600; 10,400; 11,200; 12,000; 12,800; 13,600; 14,400; 15,200; or 16,000. Any minimum and maximum values ​​can be combined to form a range, so long as the range is within 400 to 16,000 micrograms, such as a range of about 1,600 to about 9,600 micrograms, or about 3,200 to about 6,400 micrograms.

[0061] The combination of flumazenil and naltrexone may be administered together as a single composition, or may be administered as separate compositions.Thus, in some embodiments, flumazenil and naltrexone are administered in a single composition, such as the compositions described herein.In other embodiments, flumazenil and naltrexone are administered simultaneously or sequentially as separate compositions.The composition may be appropriately formulated to allow immediate release, delayed release, or sustained release of flumazenil and naltrexone.The composition may be administered to achieve bolus delivery, rapid delivery, or slow delivery.

[0062] The combination of flumazenil and naltrexone can be administered continuously throughout the treatment period or intermittently with scheduled breaks. Thus, in some embodiments, the combination of flumazenil and naltrexone is administered by continuous dosing, in which the combination is administered continuously throughout the treatment period. For example, during a 16-day treatment period, the combination is administered continuously for 16 days. In other embodiments, the combination is administered by interrupted dosing, in which the combination is administered with a break or break between dosing blocks during the treatment period. In this context, "block of dosing" or "dosing block" refers to a period during which the combination of flumazenil and naltrexone is administered, and "interruption" refers to a period during which the combination of flumazenil and naltrexone is not administered. For example, during a 22-day treatment period, interrupted dosing includes administering the combination for 8 days, not administering the combination for the next 6 days, and administering the combination for the next 8 days (i.e., one 6-day break between two 8-day dosing blocks). In some embodiments, the interruption dosing comprises one interruption, two interruptions, three interruptions, four interruptions, five interruptions, or six interruptions, particularly one interruption.The duration of each dosing block and each interruption can be the same or different, and the frequency of interruptions can be regular or irregular.Without wishing to be bound by theory, the inventors hypothesize that during the interruption period when flumazenil and naltrexone are not administered, the interruption of administration allows the patient's neurotransmitter system to be modified, which may improve treatment results.

[0063] Treatment of depression and / or anxiety may be monitored by assessing the patient or surveying the patient using questionnaires known in the art. Assessments may be completed by the researcher, by the patient, by the caregiver, or by the researcher and the patient / caregiver. Suitable assessments include the Hamilton Depression Scale (HAM-D), Montgomery and Asberg Depression Scale (MADRS), Beck Anxiety Scale, Beck Depression Scale, Snaith-Hamilton Pleasure Scale, Social and Occupational Functioning Scale (SOFAS), Cheers Scale, Generalized Anxiety Disorder 7-item Scale (GAD-7), Barratt Impulsivity Scale, Medication Checklist, and functional assessments and / or self-report scales targeting symptoms such as irritability, substance use, fatigue and insomnia, weight loss, lack of interest in sexual activity, feelings of guilt, hopelessness, or fear of being punished.

[0064] In another aspect of the present invention, there is provided the use of a combination of flumazenil and naltrexone, or pharma- ceutically acceptable salts thereof, for treating depression, wherein the flumazenil and naltrexone are in a weight ratio of about 300:1 to about 2:1. There is also provided the use of a combination of flumazenil and naltrexone, or pharma- ceutically acceptable salts thereof, for treating anxiety, wherein the flumazenil and naltrexone are in a weight ratio of about 300:1 to about 2:1.

[0065] In another aspect of the present invention, there is provided a combination of flumazenil and naltrexone, or pharma- ceutically acceptable salts thereof, for use in the treatment of depression, wherein the flumazenil and naltrexone are in a weight ratio of about 300:1 to about 2:1. There is also provided a combination of flumazenil and naltrexone, or pharma- ceutically acceptable salts thereof, for use in the treatment of anxiety, wherein the flumazenil and naltrexone are in a weight ratio of about 300:1 to about 2:1.

[0066] In another aspect of the present invention, there is provided the use of flumazenil or a pharma- ceutically acceptable salt thereof in the manufacture of a medicament for the treatment of depression, wherein the medicament is adapted for use in combination with naltrexone or a pharma- ceutically acceptable salt thereof, wherein the flumazenil and naltrexone are in a weight ratio of about 300:1 to about 2:1. There is also provided the use of flumazenil or a pharma- ceutically acceptable salt thereof in the manufacture of a medicament for the treatment of anxiety, wherein the medicament is adapted for use in combination with naltrexone or a pharma- ceutically acceptable salt thereof, wherein the flumazenil and naltrexone are in a weight ratio of about 300:1 to about 2:1.

[0067] In another aspect of the present invention, there is provided the use of naltrexone or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of depression, wherein the medicament is adapted for use in combination with flumazenil or a pharmaceutically acceptable salt thereof, wherein the flumazenil and naltrexone are in a weight ratio of about 300:1 to about 2:1. There is also provided the use of naltrexone or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of anxiety, wherein the medicament is adapted for use in combination with flumazenil or a pharmaceutically acceptable salt thereof, wherein the flumazenil and naltrexone are in a weight ratio of about 300:1 to about 2:1. There is also provided the use of naltrexone or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of PTSD, wherein the medicament is adapted for use in combination with flumazenil or a pharmaceutically acceptable salt thereof, wherein the flumazenil and naltrexone are in a weight ratio of about 300:1 to about 2:1.

[0068] In some embodiments, flumazenil and naltrexone are administered in a single composition, such as those described herein. In other embodiments, flumazenil and naltrexone are administered simultaneously or sequentially as separate compositions. EXAMPLES

[0069] Example 1 - Parenteral Formulation A formulation of flumazenil and naltrexone for subcutaneous infusion was prepared containing the following ingredients: [Table 1]

[0070] Subcutaneous infusion (30 mL solution) contains 15,000 micrograms of flumazenil and 1,200 micrograms of naltrexone hydrochloride. All components were weighed or measured immediately prior to use.

[0071] The flumazenil 7.5% / naltrexone hydrochloride 0.6% stock powder components used in the above formulations were prepared using the following ingredients: [Table 2]

[0072] The formulation can be prepared by the following procedure: Flumazenil / naltrexone stock powder, sodium chloride, and benzyl alcohol are added sequentially to 25 mL of sterile water and mixed continuously until uniform to form a homogenous liquid-like dispersion. Additional sterile water is added to the mixture to make a 30 mL batch size and mixed until uniform to form a homogenous liquid-like dispersion. If the pH is above 4.8, the pH can be adjusted to 4.6-4.8 by adding hydrochloric acid solution as needed. Adjusting the pH to 4.6-4.8 will result in a clear, homogenous solution. If a clear solution is not obtained, the dispersion can be heated to 45°C to facilitate dissolution. For storage, the solution can be filtered through a 0.22 μm sterile filter and placed into suitable dispensing containers, such as sterile, sealed, light-resistant unit dose injection vials.

[0073] Example 2 - Therapeutic Study This study focuses on evaluating the combination of flumazenil and naltrexone at specific doses and ratios for the treatment of treatment-resistant major depressive disorder.

[0074] The study will recruit 10 patients, primarily those coming as inpatients or outpatients for the treatment of treatment-resistant major depressive disorder, who meet the necessary criteria. Inclusion criteria include patients with major depressive disorder showing any symptoms according to the DSM-5 diagnostic criteria and who have failed three or more trials of antidepressant treatment of adequate dose and duration, which may include neurostimulation and / or completed structured psychotherapy. Exclusion criteria include patients with active substance abuse disorder, patients suffering from epilepsy or with a history of seizures or attacks, pregnant or breastfeeding patients, patients taking more than 5 mg equivalent of diazepam, patients under the age of 18, or patients unable or unwilling to provide informed consent.

[0075] The treatment plan for the study is described below: · Days 0–4: Flumazenil 1–15,000 micrograms and naltrexone 1,200 micrograms administered subcutaneously. · Days 5 to 8: Flumazenil 2 to 15,000 micrograms and naltrexone 1,200 micrograms subcutaneously. Days 8-14: Rest - no treatment. · Days 14 to 18: Flumazenil 3 to 15,000 micrograms and naltrexone 1,200 micrograms subcutaneously. · Days 18 to 22: Flumazenil 4 to 15,000 micrograms and naltrexone 1,200 micrograms subcutaneously.

[0076] Participants will also be required to take anti-epileptic medication for the first six weeks of the study. Treatment for major depressive disorder will continue as usual for all participants, and participants will be allowed to continue seeing their usual treating psychiatrist.

[0077] The subcutaneous drops prepared in Example 1 were used in this study. Thus, each subcutaneous drop contained 15,000 micrograms of flumazenil and 1,200 micrograms of naltrexone, with a total volume of 30 mL and a pH of 4.7. A sterile 25-gauge butterfly needle was inserted into the subcutaneous tissue of the abdomen using clean technique and connected to a portable syringe pump to allow for each 30 mL subcutaneous drop.

[0078] On the first treatment day (day 0), an initial interview was conducted, antiepileptic medication was initiated, infusion 1 was started, and blood tests for complete blood count, electrolytes and liver function tests, and other clinically required phlebotomy tests were ordered. On day 4, an on-treatment interview was conducted, infusion 1 was removed, and infusion 2 was started. On day 8, an on-treatment interview was conducted, and infusion 2 was removed. On day 14, an on-treatment interview was conducted, and infusion 3 was started. On day 18, an on-treatment interview was conducted, infusion 3 was removed, and infusion 4 was started. On day 22, an on-treatment interview was conducted, infusion 4 was removed, and blood tests for complete blood count, electrolytes and liver function tests, and other clinically required phlebotomy tests were ordered. Follow-up interviews were then conducted at weeks 6 and 12, and post-treatment interviews were conducted. The interviews included the assessments described herein.

[0079] The flumazenil dose was 15,000 micrograms over each infusion for four days, which is equivalent to 3,750 micrograms per day, or 937.5 micrograms per hour. The total dose of flumazenil during the study was 60,000 micrograms. The naltrexone dose was 1,200 micrograms over each infusion for four days, which is equivalent to 300 micrograms per day, or 12.5 micrograms per hour. The total dose of naltrexone during the study was 4,800 micrograms.

[0080] Participants experienced improvements in symptoms associated with major depressive disorder over the course of treatment, as shown below:

[0081] Patient outcomes were as follows: [Table 3] [Table 4] [Table 5] [Table 6] [Table 7]

[0082] The results show improvement in each patient's depression scores and ability to function in daily life.

[0083] Patient 1 continued to have symptoms of depression and anxiety until completion of infusion 3 on day 18 when dramatic improvement was noted. The patient observed reduced anxiety, improved ability to focus on positive thoughts, improved mood, and better concentration. Continued improvement was observed during infusion 4 and continued after completion of treatment, although regression was observed following elective surgery and post-operative pain, which resolved by the 12-week follow-up.

[0084] Patient 2 showed improvement in function during infusion 1, showering for the first time in 2 weeks and conversing with her work experience supervisor and coworkers, improved concentration was observed during infusion 2, and her depression medication (quetiapine) was reduced from 50 mg to 25 mg, but even at 25 mg there was no effect. During the rest period from day 8 to day 14, an adverse event occurred due to an interaction between phenytoin and oral contraceptives. During infusion 4, a setback occurred due to an injury to her back and the death of a pet. An increase in appetite was also observed. However, objective improvements were observed at both the 6-week and 12-week follow-up meetings.

[0085] Patient 3 saw improvement in function during infusion 1, becoming less anxious and more calm in the mornings starting on day 2. On days 3 and 4, longer and more refreshing sleep was observed, with more energy. During infusion 2, the initial improvement was lost or less pronounced, and insomnia, occasional agitation, early awakening, and a slight decrease in energy were observed. After a 6-day hiatus, the patient's symptoms remained relatively unchanged except for an increase in appetite, but no weight gain was observed. Similarly, the patient's symptoms remained unchanged between infusions 3 and 4. At 6-week follow-up, the patient showed continued clinically significant improvement, and a partially sustained increase in libido was observed.

[0086] Improvements in the Beck Depression Scale, MADRS scores, and overall SOFAS scores were observed in all patients.

[0087] Example 3 - Nasal Spray Formulation A formulation of flumazenil and naltrexone for nasal application was prepared containing the following ingredients: [Table 8]

[0088] Naltrexone stock solution was prepared by adding naltrexone hydrochloride to sterile water for injection (9 mL) and continuously mixing to provide a homogenous liquid solution. Additional sterile water was added to provide 10 mL of solution and mixing was continued until all solid particles were completely dissolved.

[0089] The benzalkonium chloride stock solution was prepared by slowly adding 0.2 mL of benzalkonium chloride solution (50%) to 9 mL of sterile water. The composition was mixed to provide a homogenous liquid solution. Additional water was added to bring the volume to 10 mL and stirring was continued until all solid particles were completely dissolved.

[0090] Flumazenil, sodium chloride and sodium carboxymethylcellulose were milled together to form a fine, uniform powder mixture.

[0091] The components were added sequentially in the following order to sterile water for injection (7.5 mL): Each ingredient was added after the previous ingredient had been completely added and dispersed: Naltrexone hydrochloride 1% stock solution (1.667mL) A homogeneous powder blend of flumazenil, sodium chloride and sodium carboxymethylcellulose Benzalkonium chloride 1% stock solution (0.2 mL). The ingredients were mixed continuously until all solid particles were completely dispersed.

[0092] A sample of the composition was tested for pH and found to be between 4.6 and 4.8. If the pH exceeds 4.8, hydrochloric acid (10% solution) is added dropwise to the mixture, taking care not to allow the pH to fall below 4.6.

[0093] The solution was then made up to 10 mL with sterile water and mixed.

[0094] The solution is then transferred to a suitable dispenser for intranasal delivery.

[0095] Where a prior art publication is referred to herein, it should be understood that such reference is not an admission that the publication forms part of the common general knowledge in the art in Australia or any other country.

Claims

1. A pharmaceutical composition comprising flumazenil and naltrexone, or a pharma- ceutically acceptable salt thereof, wherein the flumazenil and naltrexone are present in a weight ratio of about 25:1 to about 10:

1.

2. 10. The pharmaceutical composition of claim 1, wherein the composition is in the form of a single dosage unit.

3. 3. The pharmaceutical composition of claim 2, wherein the single dosage unit is formulated for administration over about 4 days.

4. 4. The pharmaceutical composition of claim 2 or claim 3, wherein a single dosage unit contains flumazenil in an amount providing a daily dose in the range of about 250 to about 1,000 micrograms.

5. 5. The pharmaceutical composition of any one of claims 2 to 4, wherein a single dosage unit contains naltrexone in an amount providing a daily dose in the range of about 25 to about 7,500 micrograms.

6. 6. The pharmaceutical composition of any one of claims 2 to 5, wherein flumazenil is present in a single dosage unit in an amount ranging from about 1,000 to about 30,000 micrograms.

7. 7. The pharmaceutical composition of any one of claims 2 to 6, wherein naltrexone is present in a single dosage unit in an amount ranging from about 100 to about 4,000 micrograms.

8. The pharmaceutical composition of any one of claims 1 to 7, wherein the composition is formulated for subcutaneous administration.

9. The pharmaceutical composition of any one of claims 1 to 7, wherein the composition is formulated for nasal delivery.

10. 1. A pharmaceutical combination for the treatment of depression comprising a combination of flumazenil and naltrexone, or a pharma- ceutically acceptable salt thereof, wherein the flumazenil and naltrexone are administered in a weight ratio of about 25:1 to about 10:

1.

11. 1. A pharmaceutical combination for the treatment of anxiety comprising a combination of flumazenil and naltrexone, or a pharma- ceutically acceptable salt thereof, wherein the flumazenil and naltrexone are administered in a weight ratio of about 300:1 to about 2:

1.

12. 1. A pharmaceutical combination for the treatment of post-traumatic stress disorder comprising a combination of flumazenil and naltrexone, or a pharma- ceutically acceptable salt thereof, wherein the flumazenil and naltrexone are administered in a weight ratio of about 25:1 to about 10:

1.

13. A pharmaceutical combination according to any one of claims 10 to 12, wherein one or more of the following apply: i) flumazenil is administered to provide a daily dose in the range of about 250 to about 7,500 micrograms; ii) naltrexone is administered to provide a daily dose in the range of about 25 to about 1,000 micrograms; iii) flumazenil is administered to provide a total dose in the range of about 4,000 to about 120,000 micrograms over the course of treatment; and iv) Naltrexone is administered over the course of treatment to provide a total dose ranging from about 400 to about 16,000 micrograms.

14. The pharmaceutical combination according to any one of claims 10 to 13, wherein flumazenil and naltrexone are administered in a single composition.

15. The pharmaceutical combination of claim 14, wherein a single composition comprises a pharmaceutical composition according to any one of claims 1 to 9.

16. The pharmaceutical combination according to any one of claims 10 to 14, wherein flumazenil and naltrexone are administered by continuous dosing.

17. The pharmaceutical combination according to any one of claims 10 to 15, wherein flumazenil and naltrexone are administered by interrupted dosing.

18. Use of flumazenil or a pharma- ceutical acceptable salt thereof in the manufacture of a medicament for the treatment of depression and / or anxiety and / or post-traumatic stress disorder, wherein the medicament is adapted for use in combination with naltrexone or a pharma- ceutical acceptable salt thereof, wherein the flumazenil and naltrexone are in a weight ratio of about 25:1 to about 10:

1.

19. Use of naltrexone, or a pharma- ceutical acceptable salt thereof, in the manufacture of a medicament for the treatment of depression and / or anxiety and / or post-traumatic stress disorder, wherein the medicament is adapted for use in combination with flumazenil, or a pharma- ceutical acceptable salt thereof, wherein the flumazenil and naltrexone are in a weight ratio of about 25:1 to about 10:

1.

20. A kit comprising one or more pharmaceutical compositions according to any one of claims 1 to 9 and a delivery device.